Ferroptosis inhibitor alleviates sorafenib-induced cardiotoxicity by attenuating KLF11-mediated FSP1-dependent ferroptosis
International Journal of Biological Sciences · 2024
DOI: 10.7150/ijbs.86479 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Biological Sciences, 2024. Verfasst von Yilan Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, the Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China. Hauptthemen laut MEDLINE: Cardiotoxicity, Ferroptosis, Repressor Proteins, S100 Calcium-Binding Protein A4. Die Arbeit wurde bisher 18-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Sorafenib is a standard first-line drug for advanced hepatocellular carcinoma, but the serious cardiotoxic effects restrict its therapeutic applicability. Here, we show that iron-dependent ferroptosis plays a vital role in sorafenib-induced cardiotoxicity. Remarkably, our in vivo and in vitro experiments demonstrated that ferroptosis inhibitor application neutralized sorafenib-induced heart injury. By analyzing transcriptome profiles of adult human sorafenib-treated cardiomyocytes, we found that Krüppel-like transcription factor 11 (KLF11) expression significantly increased after sorafenib stimulation. Mechanistically, KLF11 promoted ferroptosis by suppressing transcription of ferroptosis suppressor protein 1 (FSP1), a seminal breakthrough due to its ferroptosis-repressing properties. Moreover, FSP1 knockdown showed equivalent results to glutathione peroxidase 4 (GPX4) knockdown, and FSP1 overexpression counteracted GPX4 inhibition-induced ferroptosis to a substantial extent. Cardiac-specific overexpression of FSP1 and silencing KLF11 by an adeno-associated virus serotype 9 markedly improved cardiac dysfunction in sorafenib-treated mice. In summary, FSP1-mediated ferroptosis is a crucial mechanism for sorafenib-provoked cardiotoxicity, and targeting ferroptosis may be a promising therapeutic strategy for alleviating sorafenib-induced cardiac damage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, the Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China.
- Key Laboratory of Myocardial Ischemia, Ministry of Education, Harbin Medical University, Harbin 150086, China.
- Cancer Centre, Faculty of Health Sciences, University of Macau, Macau, China.
- Ministry of Education Frontiers Science Center for Precision Oncology, University of Macau, Macau, China.
- Department of Pathology, the Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China.
Zitieren
APA
Li, Y., Yan, J., Sun, H., Liang, Y., Zhao, Q., Yu, S., & Zhang, Y. (2024). Ferroptosis inhibitor alleviates sorafenib-induced cardiotoxicity by attenuating KLF11-mediated FSP1-dependent ferroptosis. International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.86479
Vancouver
Li Y, Yan J, Sun H, Liang Y, Zhao Q, Yu S, et al. Ferroptosis inhibitor alleviates sorafenib-induced cardiotoxicity by attenuating KLF11-mediated FSP1-dependent ferroptosis. International Journal of Biological Sciences. 2024. doi:10.7150/ijbs.86479
BibTeX
@article{Li2024,
author = {Li, Yilan and Yan, Jingru and Sun, Heng and Liang, Yating and Zhao, Qianqian and Yu, Shan and Zhang, Yao},
title = {Ferroptosis inhibitor alleviates sorafenib-induced cardiotoxicity by attenuating KLF11-mediated FSP1-dependent ferroptosis},
journal = {International Journal of Biological Sciences},
year = {2024},
doi = {10.7150/ijbs.86479}
}
EUVIMED